PATIENT INFORMATION

have a history of renal and/or liver disease,
convulsions, asthma or allergic respiratory disorders, or recent administration
of gadolinium-based contrast. GBCAs increase the risk for NSF among patients with
impaired elimination of the drugs. To counsel patients at risk for NSF:

Describe the clinical manifestations of NSF

Describe procedures to screen for the detection of renal
impairment

Instruct the patients to contact their physician if they
develop signs or symptoms of NSF following OMNISCAN administration such as
burning, itching, swelling, scaling, hardening and tightening of the skin; red
or dark patches on the skin; stiffness in joints with trouble moving, bending
or straightening the arms, hands, legs or feet; pain deep in the hip bones or
ribs; or muscle weakness.

Last reviewed on RxList: 12/5/2014
This monograph has been modified to include the generic and brand name in many instances.